Literature DB >> 26446491

Impact of Duodenal-Jejunal Exclusion on Satiety Hormones.

Charlotte de Jonge1,2, Sander S Rensen3, Froukje J Verdam4, Royce P Vincent5, Steve R Bloom6, Wim A Buurman7, Carel W le Roux8,9, Nicole D Bouvy10, Jan Willem M Greve11,12.   

Abstract

OBJECTIVE: Bariatric procedures that exclude the proximal small intestine lead to significant weight loss which is probably mediated by changes in hormones that alter appetite, such as peptide YY (PYY), ghrelin, cholecystokinin (CCK), and leptin. Here, the effect of the non-surgical duodenal-jejunal bypass liner (DJBL) on concentrations of hormones implicated in appetite control was investigated.
SUBJECTS: A two-center prospective study was conducted between January and December 2010. Seventeen obese subjects with type 2 diabetes were treated with the DJBL for 24 weeks. Fasting concentrations of leptin and meal responses of plasma PYY, CCK, and ghrelin were determined prior to and after implantation of the DJBL.
RESULTS: At baseline, subjects had an average body weight of 116.0 ± 5.8 kg. One week after implantation, subjects had lost 4.3 ± 0.6 kg (p < 0.01), which progressed to 12.7 ± 1.3 kg at week 24 (p < 0.01). Postprandial concentrations of PYY and ghrelin increased (baseline vs. week 1 vs. week 24 PYY: 2.6 ± 0.2 vs. 4.1 ± 0.4 vs. 4.1 ± 0.7 nmol/L/min and ghrelin: 7.8 ± 1.8 vs. 11.0 ± 1.8 vs. 10.6 ± 1.8 ng/mL/min, all p < 0.05). In parallel, the CCK response decreased (baseline vs. week 1 vs. week 24: 434 ± 51 vs. 229 ± 52 vs. 256 ± 51 pmol/L/min, p < 0.01). Fasting leptin concentrations also decreased (baseline vs. week 24: 98 ± 17 vs. 53 ± 10 ng/mL, p < 0.01).
CONCLUSIONS: DJBL treatment induces weight loss paralleled by changes in concentrations of hormones involved in appetite control.

Entities:  

Keywords:  Bariatric surgery; Gut hormones; Obesity; Satiety

Mesh:

Substances:

Year:  2016        PMID: 26446491     DOI: 10.1007/s11695-015-1889-y

Source DB:  PubMed          Journal:  Obes Surg        ISSN: 0960-8923            Impact factor:   4.129


  43 in total

Review 1.  Leptin and the control of body weight: a review of its diverse central targets, signaling mechanisms, and role in the pathogenesis of obesity.

Authors:  Ashwini Oswal; Giles Yeo
Journal:  Obesity (Silver Spring)       Date:  2009-07-30       Impact factor: 5.002

Review 2.  Structure, regulation and function of ghrelin.

Authors:  Takahiro Sato; Yuki Nakamura; Yuki Shiimura; Hideko Ohgusu; Kenji Kangawa; Masayasu Kojima
Journal:  J Biochem       Date:  2011-10-31       Impact factor: 3.387

Review 3.  Cholecystokinin.

Authors:  Graham J Dockray
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2012-02       Impact factor: 3.243

Review 4.  Gastrointestinal hormones and food intake.

Authors:  April D Strader; Stephen C Woods
Journal:  Gastroenterology       Date:  2005-01       Impact factor: 22.682

Review 5.  Ghrelin's second life: from appetite stimulator to glucose regulator.

Authors:  Pieter-Jan Verhulst; Inge Depoortere
Journal:  World J Gastroenterol       Date:  2012-07-07       Impact factor: 5.742

6.  Macrophage inhibitory factor, plasminogen activator inhibitor-1, other acute phase proteins, and inflammatory mediators normalize as a result of weight loss in morbidly obese subjects treated with gastric restrictive surgery.

Authors:  F M H van Dielen; W A Buurman; M Hadfoune; J Nijhuis; J W Greve
Journal:  J Clin Endocrinol Metab       Date:  2004-08       Impact factor: 5.958

7.  A multicenter, randomized efficacy study of the EndoBarrier Gastrointestinal Liner for presurgical weight loss prior to bariatric surgery.

Authors:  Ruben Schouten; Carianne S Rijs; Nicole D Bouvy; Wim Hameeteman; Ger H Koek; Ignace M C Janssen; Jan-Willem M Greve
Journal:  Ann Surg       Date:  2010-02       Impact factor: 12.969

8.  Basal and postprandial plasma levels of PYY, ghrelin, cholecystokinin, gastrin and insulin in women with moderate and morbid obesity and metabolic syndrome.

Authors:  K Zwirska-Korczala; S J Konturek; M Sodowski; M Wylezol; D Kuka; P Sowa; M Adamczyk-Sowa; M Kukla; A Berdowska; J F Rehfeld; W Bielanski; T Brzozowski
Journal:  J Physiol Pharmacol       Date:  2007-03       Impact factor: 3.011

9.  Inhibition of food intake in obese subjects by peptide YY3-36.

Authors:  Rachel L Batterham; Mark A Cohen; Sandra M Ellis; Carel W Le Roux; Dominic J Withers; Gary S Frost; Mohammad A Ghatei; Stephen R Bloom
Journal:  N Engl J Med       Date:  2003-09-04       Impact factor: 91.245

10.  Progressive rise in gut hormone levels after Roux-en-Y gastric bypass suggests gut adaptation and explains altered satiety.

Authors:  C M Borg; C W le Roux; M A Ghatei; S R Bloom; A G Patel; S J B Aylwin
Journal:  Br J Surg       Date:  2006-02       Impact factor: 6.939

View more
  7 in total

1.  EndoBarrier® in Grade I Obese Patients with Long-Standing Type 2 Diabetes: Role of Gastrointestinal Hormones in Glucose Metabolism.

Authors:  Nuria Vilarrasa
Journal:  Obes Surg       Date:  2017-01       Impact factor: 4.129

Review 2.  The Gut as an Endocrine Organ: Role in the Regulation of Food Intake and Body Weight.

Authors:  Audrey Melvin; Carel W le Roux; Neil G Docherty
Journal:  Curr Atheroscler Rep       Date:  2016-08       Impact factor: 5.113

3.  Adverse Events of the Duodenal-Jejunal Bypass Liner: a Systematic Review.

Authors:  Bark Betzel; Joost P H Drenth; Peter D Siersema
Journal:  Obes Surg       Date:  2018-11       Impact factor: 4.129

4.  Endobarrier® in Grade I Obese Patients with Long-Standing Type 2 Diabetes: Role of Gastrointestinal Hormones in Glucose Metabolism.

Authors:  Nuria Vilarrasa; Amador García Ruiz de Gordejuela; Anna Casajoana; Xevi Duran; Silvia Toro; Eduard Espinet; Manoel Galvao; Joan Vendrell; Rafael López-Urdiales; Manuel Pérez; Jordi Pujol
Journal:  Obes Surg       Date:  2017-03       Impact factor: 4.129

5.  Metabolic improvement in obese patients after duodenal-jejunal exclusion is associated with intestinal microbiota composition changes.

Authors:  C de Jonge; S Fuentes; E G Zoetendal; N D Bouvy; R Nelissen; W A Buurman; J W Greve; W M de Vos; S S Rensen
Journal:  Int J Obes (Lond)       Date:  2019-02-14       Impact factor: 5.095

6.  A randomised controlled trial of a duodenal-jejunal bypass sleeve device (EndoBarrier) compared with standard medical therapy for the management of obese subjects with type 2 diabetes mellitus.

Authors:  Michael Alan Glaysher; Aruchuna Mohanaruban; Christina Gabriele Prechtl; Anthony P Goldstone; Alexander Dimitri Miras; Joanne Lord; Navpreet Chhina; Emanuela Falaschetti; Nicholas Andrew Johnson; Werd Al-Najim; Claire Smith; Jia V Li; Mayank Patel; Ahmed R Ahmed; Michael Moore; Neil Poulter; Stephen Bloom; Ara Darzi; Carel Le Roux; James P Byrne; Julian P Teare
Journal:  BMJ Open       Date:  2017-11-15       Impact factor: 2.692

7.  The Effect of 6 and 12 months Duodenal-Jejunal Bypass Liner Treatment on Obesity and Type 2 Diabetes: a Crossover Cohort Study.

Authors:  Selwyn van Rijn; Bark Betzel; Charlotte de Jonge; David P J van Dijk; Ignace M Janssen; Frits J Berends; Nicole D Bouvy; Jan Willem M Greve
Journal:  Obes Surg       Date:  2018-05       Impact factor: 4.129

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.